Cone damage in patients receiving high-dose irofulven treatment

被引:7
作者
Lee, MS
Gupta, N
Penson, RT
Loewenstein, J
Wepner, MS
Seiden, MV
Milam, AH
机构
[1] Cleveland Clin Fdn, Cole Eye Inst, Cleveland, OH 44124 USA
[2] Univ Penn, M Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA
[3] Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA
[4] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA
[5] Massachusetts Eye & Ear Infirm, Retina Serv, Boston, MA 02114 USA
关键词
OPHTHALMIC TOXICITY; PACLITAXEL; 6-HYDROXYMETHYLACYLFULVENE; DYSFUNCTION; RETINOPATHY; BLINDNESS;
D O I
10.1001/archopht.123.1.29
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objectives: To describe the clinical, perimetric, and electroretinographic (ERG) results of 4 patients with cone dysfunction following irofulven treatment including the histopathologic and immunocytochemical features of one patient's retinas. Design: Observational case series. Methods: The patients were examined clinically, including perimetric and ERG evaluations. Eyes from patient 1 and healthy postmortem eyes were processed for histopathologic and immunocytochemistry studies with antibodies specific for cones, rods, and reactive Muller cells. Main Outcome Measures: Clinical signs and symptoms, perimetry, ERG, retinal histopathologic and immunocytochemistry study results. Results: All 4 patients had ERG changes consistent with abnormal cone responses and relatively normal rod responses. Compared with control eyes, the retina of patient 1 had approximately half the normal numbers of macular cones and fewer peripheral cones. The number of rods were normal but all rod and cone outer segments were shortened. Conclusion: High-dose irofulven treatment causes cone-specific damage with relative sparing of rods.
引用
收藏
页码:29 / 34
页数:6
相关论文
共 24 条
[1]  
ALEXANDRE J, 2001, P AN M AM SOC CLIN, V20, pB83
[2]   OPTIC-NERVE DISTURBANCES - A NEW FORM OF PACLITAXEL NEUROTOXICITY [J].
CAPRI, G ;
TARENZI, E ;
FULFARO, F ;
GIANNI, L ;
CARACENI, A ;
MARTINI, C ;
SCAIOLI, V .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (14) :1099-1101
[3]   TRANSIENT BLINDNESS AND SEIZURE ASSOCIATED WITH CISPLATIN THERAPY [J].
CATTANEO, MT ;
FILIPAZZI, V ;
PIAZZA, E ;
DAMIANI, E ;
MANCARELLA, G .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1988, 114 (05) :528-530
[4]   PARANEOPLASTIC RETINOPATHY PRESENTING AS A CONE DYSFUNCTION WITH ACHROMATOPSIA [J].
COGAN, DG ;
KUWABARA, T ;
CURRIE, J ;
KATTAH, J .
KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 1990, 197 (02) :156-158
[5]  
Heckenlively JR, 2000, ARCH OPHTHALMOL-CHIC, V118, P1525
[6]   Ophthalmic toxicity following paclitaxel infusion [J].
Hofstra, LS ;
deVries, EGE ;
Willemse, PHB .
ANNALS OF ONCOLOGY, 1997, 8 (10) :1053-1053
[7]   OCULAR COMPLICATIONS OF SYSTEMIC CANCER-CHEMOTHERAPY [J].
IMPERIA, PS ;
LAZARUS, HM ;
LASS, JH .
SURVEY OF OPHTHALMOLOGY, 1989, 34 (03) :209-230
[8]  
JACOBSON DM, 1995, ARCH OPHTHALMOL-CHIC, V113, P1580
[9]   Persistent severe visual and electroretinographic abnormalities after intravenous cisplatin therapy [J].
Katz, BJ ;
Ward, JH ;
Digre, KB ;
Creel, DJ ;
Mamalis, N .
JOURNAL OF NEURO-OPHTHALMOLOGY, 2003, 23 (02) :132-135
[10]  
MacDonald JR, 1997, CANCER RES, V57, P279